Compass Pathways Hits 52-Week High of $12.48 on Psilocybin Trial Momentum
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
psilocybinmental-health
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Compass Pathways PLC shares traded at a 52-week high of $12.48 on 29 May 2026. The move extends a rally from the $8.50 level observed in late April. This represents the stock's highest intraday price since May 2025, when shares briefly touched $13.10. Data was reported by investing.com on 29 May 2026.
The peak aligns with a critical phase for the company's lead asset, COMP360 psilocybin therapy. The last significant rally for Compass Pathways occurred in November 2025, when shares gained 45% following positive interim data readouts. That move was driven by investor confidence in the program's clinical trajectory.
The current macro backdrop for biotech remains challenging, with the Nasdaq Biotechnology Index (NBI) down 2% year-to-date. High interest rates continue to pressure valuations for pre-revenue companies. The Federal Funds Rate target stands at 4.25-4.50%, maintaining a high cost of capital.
The immediate catalyst for the recent appreciation is the approaching data readout for the pivotal Phase III trial in treatment-resistant depression. Trial enrollment completion was confirmed earlier this month. This removes a key execution risk that had weighed on the stock throughout early 2026.
The share price of $12.48 reflects a significant recovery from its 52-week low of $6.22 recorded in October 2025. The current level represents a 101% increase from that low. Compass Pathways' market capitalization now stands at approximately $780 million based on the latest closing share count.
The stock's performance has significantly diverged from its sector. While the NBI is negative for the year, Compass Pathways has posted a year-to-date gain of 32% as of 28 May. This outperformance highlights the stock-specific nature of the current rally.
| Metric | 29 May 2026 | 52-Week Low (Oct 2025) | Change |
|---|---|---|---|
| Share Price | $12.48 | $6.22 | +101% |
| 30-Day Avg Volume | 1.2M | 850k | +41% |
The company reported cash and equivalents of $196.3 million as of 31 March 2026. This provides an estimated runway of approximately two years at the current quarterly cash burn rate. The cash position equates to roughly $3.15 per share, a key metric for value-focused investors.
The rally signals renewed institutional belief in the psychedelic therapy sector. Companies with advanced clinical programs, like MindMed (MNMD) and Cybin Inc. (CYBN), have seen correlated gains of 8-12% over the same fortnight. This suggests capital is rotating into the niche based on a de-risking narrative.
Specialty pharmaceutical firms with depression portfolios face a potential long-term headwind. Intra-Cellular Therapies (ITCI), which markets Caplyta for bipolar depression, has underperformed the broader market by 5% in the last month. Investors may be pricing in future competition from novel mechanisms of action.
A key counter-argument is the significant regulatory and commercial uncertainty that remains. The U.S. Drug Enforcement Administration has not yet rescheduled psilocybin, a necessary step for any prescription market. This overhang could cap valuation multiples until a clearer pathway emerges.
Positioning data from recent exchange filings shows hedge funds like Perceptive Advisors and RA Capital have maintained or increased their stakes. Retail options flow indicates elevated call buying for July and September expiries, targeting strikes between $15 and $20, reflecting bullish speculation on trial data.
The primary catalyst is the topline results from the Phase III COMP 005 trial in treatment-resistant depression. Management has guided for a data readout in the fourth quarter of 2026. A positive result would likely trigger an immediate New Drug Application submission to the U.S. FDA.
Investors should monitor the upcoming American Psychiatric Association annual meeting in late June 2026. Compass Pathways is expected to present additional analyses from its Phase IIb trial. Any new safety or efficacy signals could move the stock.
Key technical levels provide a framework for price action. Immediate resistance sits near the May 2025 high of $13.10. A sustained break above this level could target the $15.00 area. Support is established around the 50-day moving average, currently at $10.75. A breach below $10.00 would signal a breakdown of the current uptrend.
The high price reflects professional investor confidence in a specific binary event: Phase III trial results. For retail investors, this concentration of risk means volatility will remain extreme. The stock could react 40-60% in either direction based on the clinical data outcome. This is not a suitable investment for those seeking stability or income.
It mirrors early moves seen in stocks like Sage Therapeutics (SAGE) ahead of the brexanolone (Zulresso) approval in 2019. Sage shares rallied over 120% in the six months prior to its FDA advisory committee meeting. However, commercial outcomes diverged sharply, with Zulresso generating less than $20 million in annual sales, highlighting the difference between clinical success and market adoption.
Analyst projections for the treatment-resistant depression market targeted by COMP360 range from $3 billion to $5 billion annually in the United States alone. This assumes pricing comparable to other advanced psychiatric therapies, such as Spravato (esketamine), which costs approximately $4,700 to $6,800 per treatment course. Market penetration would be gradual, dependent on insurance coverage and clinician training.
The stock's peak prices in perfect execution ahead of a pivotal data readout that will determine the company's fundamental value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.